These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17928819)

  • 1. Individualized compared with conventional dosing of enoxaparin.
    Barras MA; Duffull SB; Atherton JJ; Green B
    Clin Pharmacol Ther; 2008 Jun; 83(6):882-8. PubMed ID: 17928819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative.
    Spinler SA; Ou FS; Roe MT; Gibler WB; Ohman EM; Pollack CV; Alexander KP; Peterson ED
    Pharmacotherapy; 2009 Jun; 29(6):631-8. PubMed ID: 19476416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study.
    Marlovits S; Striessnig G; Schuster R; Stocker R; Luxl M; Trattnig S; Vécsei V
    Arthroscopy; 2007 Jul; 23(7):696-702. PubMed ID: 17637403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients].
    Omran H; Hammerstingl C; Paar WD;
    Med Klin (Munich); 2007 Oct; 102(10):809-15. PubMed ID: 17928964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes.
    LaPointe NM; Chen AY; Alexander KP; Roe MT; Pollack CV; Lytle BL; Ohman ME; Gibler BW; Peterson ED
    Arch Intern Med; 2007 Jul; 167(14):1539-44. PubMed ID: 17646609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations.
    Barras MA; Duffull SB; Atherton JJ; Green B
    Ther Drug Monit; 2010 Aug; 32(4):482-8. PubMed ID: 20592650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Outpatient treatment of deep vein thrombosis with low-molecular-weight heparins. Experience from an open, prospective study in daily practice].
    Heidenreich C; Hohmann V; Bramlage P
    Med Klin (Munich); 2009 Jan; 104(1):20-7. PubMed ID: 19142593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome.
    Hulot JS; Montalescot G; Lechat P; Collet JP; Ankri A; Urien S
    Clin Pharmacol Ther; 2005 Jun; 77(6):542-52. PubMed ID: 15961985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
    Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
    Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monotherapy with enoxaparin for the prevention of recurrent venous thromboembolism.
    Castro DJ; Díaz G; Martí D; Escobar C; Ortega J; García-Rull S; Picher J; Sueiro A
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):173-7. PubMed ID: 17287635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosage of enoxaparin among obese and renal impairment patients.
    Bazinet A; Almanric K; Brunet C; Turcotte I; Martineau J; Caron S; Blais N; Lalonde L
    Thromb Res; 2005; 116(1):41-50. PubMed ID: 15850607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of bleeding events associated with short-duration therapeutic enoxaparin use in the morbidly obese.
    Hagopian JC; Riney JN; Hollands JM; Deal EN
    Ann Pharmacother; 2013 Dec; 47(12):1641-8. PubMed ID: 24259606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enoxaparin as bridging anticoagulant treatment in cardiac surgery.
    Rivas-Gándara N; Ferreira-González I; Tornos P; Torrents A; Permanyer-Miralda G; Nicolau I; Arellano-Rodrigo E; Vallejo N; Igual A; Soler-Soler J
    Heart; 2008 Feb; 94(2):205-10. PubMed ID: 17483131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.
    Morrow DA; Antman EM; Murphy SA; Qin J; Ruda M; Guneri S; Jacob AJ; Budaj A; Braunwald E;
    Am Heart J; 2007 Dec; 154(6):1078-84, 1084.e1. PubMed ID: 18035078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding events in patients receiving enoxaparin for the management of non-ST-elevation acute coronary syndrome (NSTEACS) at Dunedin Public Hospital, New Zealand.
    Al-Sallami H; Ferguson R; Wilkins G; Gray A; Medlicott NJ
    N Z Med J; 2008 Nov; 121(1285):87-95. PubMed ID: 19079441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial.
    White HD; Gallo R; Cohen M; Steg PG; Aylward PE; Bode C; Steinhubl S; Montalescot G
    Am Heart J; 2009 Jan; 157(1):125-31. PubMed ID: 19081408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety.
    Lachish T; Rudensky B; Slotki I; Zevin S
    Pharmacotherapy; 2007 Oct; 27(10):1347-52. PubMed ID: 17896889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.
    Borkgren-Okonek MJ; Hart RW; Pantano JE; Rantis PC; Guske PJ; Kane JM; Gordon N; Sambol NC
    Surg Obes Relat Dis; 2008; 4(5):625-31. PubMed ID: 18261965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
    Amin AN; Lin J; Lenhart G; Schulman KL
    Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.